Cellyan Biotechnology Co., Ltd key statistics and ratios

In fiscal 2026, Cellyan Biotechnology Co., Ltd had return on equity of -15.5%, an operating margin of -17.8%, debt equal to 9.1% of equity and a current ratio of 3.86. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cellyan Biotechnology Co., Ltd: financial ratios, annual
Fiscal year	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Gross margin	21.8%	21.3%	11.9%	10.3%
Operating margin	−14.3%	−11.7%	−11.2%	−17.8%
Net margin	8.0%	8.0%	−0.1%	−8.5%
Free-cash-flow margin	12.8%	−2.7%	2.5%	−5.9%
Return on equity	170.6%	55.0%	−0.6%	−15.5%
Return on assets	—	15.3%	−0.3%	−10.2%
Asset turnover	—	1.93	2.25	1.21
Current ratio	—	2.46	2.99	3.86
Debt to equity	—	31.4%	37.6%	9.1%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m
Effective tax rate	2.2%	12.9%	—	—
Capital spending as % of revenue	0.9%	0.3%	0.3%	0.3%
Free cash flow ÷ net income	161.5%	−33.6%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · March 31, 2026

What it owns · $13m

Short-term assets $12mLonger-term assets $1m

What it owes, and who funded it · $13m

Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $10m

Short-term assets cover short-term liabilities $12m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities $12m short-term assets against $65,275 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$2m against $133,849 of interest.

From Cellyan Biotechnology Co., Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: COSM vs HKPD HKPD vs YI HKPD vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cellyan Biotechnology Co., Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cellyan Biotechnology Co., Ltd.